A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)

NCT02708095 PHASE2 COMPLETED Results posted

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as baricitinib in participants with systemic lupus erythematosus.

Details

Lead sponsor	Eli Lilly and Company
Phase	PHASE2
Status	COMPLETED
Enrolment	314
Start date	Thu Mar 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Nov 09 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Systemic Lupus Erythematosus

Interventions

• Baricitinib
• Placebo

Countries

France, Japan, Austria, Taiwan, Poland, Mexico, South Korea, Argentina, Puerto Rico, Romania, United States, Spain